Core Research

Semax Research Overview

Semax is studied as an ACTH(4-7)-derived synthetic peptide with a Pro-Gly-Pro extension. Its experimental literature includes region-specific neurotrophin gene expression and transcriptional changes after cerebral-ischemia models. Those findings are mechanistic research observations, not evidence for a commercial “nootropic” effect.

Semax is not ACTH

The common ACTH(4-7)PGP description identifies a structural relationship to an ACTH fragment. Semax is not full-length ACTH, and evidence for ACTH itself should not automatically be assigned to Semax. Likewise, a PGP-containing fragment can have its own experimental behaviour and should be named precisely.

Neurotrophin gene expression is region-specific

In normal rat brain, Semax exposure produced rapid, region-specific changes in Bdnf and Ngf expression. Some regions showed increases while others showed decreases. PubMed.

That pattern is more informative than the slogan “Semax increases BDNF”. A whole-brain or clinical inference would discard the regional heterogeneity reported in the experiment.

Ischaemia-model transcription research

In rat cerebral-ischaemia work, Semax and PGP-related material have been associated with changes in neurotrophin/receptor transcription. PubMed. More recent transcriptomic research has also reported changes in inflammation-related gene expression in an experimental cerebral-ischaemia context. PubMed.

These studies examine molecular responses after defined experimental injury. They do not establish a clinical neuroprotective effect, cognitive enhancement or a safe human-use protocol.

How to interpret Semax evidence

Evidence detailInterpretive limit
Brain-region gene expressionA change in one region should not be generalised to the whole brain.
Neurotrophin/receptor transcriptsTranscriptional change is not equivalent to a behavioural or clinical outcome.
Cerebral-ischaemia modelsExperimental injury models do not establish treatment efficacy in people.
PGP fragment comparisonsRelated fragments should be reported as the exact tested material.

Relationship to Selank

Semax and Selank are distinct synthetic peptide families. Their PGP-related descriptions do not make them interchangeable. The Selank research overview covers its separate gene-expression evidence.

Identity and batch documentation

Exact sequence, terminal form, salt/counter-ion, mass, chromatographic result and lot identity should be confirmed from the applicable product documentation. A literature description of ACTH(4-7)PGP does not authenticate the contents of a commercial vial.

Use Batch Documentation, the HPLC guide and the mass-spectrometry guide for the analytical evidence layer.

Catalogue formats

Core Research lists Semax 10mg and Semax Refill 10mg. The refill is a separate finished presentation and requires its own cartridge/format evidence.

Research-use boundary

Core Research Semax products are supplied for laboratory research use only, not for human or veterinary use. No cognitive-enhancement, neuroprotection, dosing or administration guidance is provided.

Selected references

  1. Semax effects on BDNF and NGF gene expression in rat brain. PMID 17353092.
  2. Semax/PGP effects on neurotrophin-related expression after cerebral ischaemia. PMID 19633950.
  3. Semax-related changes in inflammatory gene expression after experimental cerebral ischaemia. PMID 34097675.